Hanx Biopharmaceuticals (Wuhan) Co., Ltd. 翰 思 艾 泰 生 物 醫 藥 科 技(武 漢)股 份 有 限 公 司 (於中華人民共和國註冊成立的股份有限公司) 全球發售 獨家保薦人、整體協調人、聯席全球協調人及聯席賬簿管理人 ICBC (扫) 工银国际 整體協調人、聯席全球協調人及聯席賬簿管理人 HAITONG | 國泰坦通 CMS # 招商指券國際 聯席全球協調人及聯席張簿管理人 ABCI()農银國際 [J浦銀國際SPDB| 胎席賬簿管理人 9 利弗莫尔证券 √ 具塔國際證券 60 老虎證券 同 山 證 國 際 来自湖北武汉的 翰恩艾泰-B(02661.HK)，于今日(12月15日)起至周四(12月18日)招股，预计2025年12月23日在港交 所挂牌上市，工银国际独家保荐。 全球發售項下的發售股份數目 : 18.321.000股H股(視乎超額配股權 行使與否而定) 1.832.100股H股(可予重新分配) 香港發售股份數目 . 國際發售股份數目 16.488.900股H股(可予重新分配及 視平超額配股權行使與否而定) 最高發售價 a 每股發售股份32.00港元,另加 ...

翰思艾泰生物医药科技(武汉)股份有限公司-B(简称：翰思艾泰)于6月2日所递交的港股招股书满6个月，于12月2日失效，递表时工银国际为其独家保荐人。 据招股书，翰思艾泰是一家拥有结构生物学、转化医学及临床开发方面自主专业技术及经验的创新生物科技公司。自2016年起，公司一直打造创新管线，包 括一款核心产品及九款其他管线的候选产品，即(i)三款针对肿瘤学的临床阶段候选药物，包括核心产品HX009及主要产品HX301及HX044;及(ii)七款临床前 阶段候选药物，包括针对自身免疫和肿瘤市场的抗体偶联药物、双特异性抗体及单克隆抗体。于往绩记录期间前，公司亦开发HX008，其已转让予一家专注 于肿瘤疗法的生物制药公司。 ...

Core Viewpoint - Hanx Biopharmaceuticals (Wuhan) Co., Ltd. plans to issue up to 21,069,700 overseas listed ordinary shares and convert 117,897,830 domestic unlisted shares into overseas listed shares for trading on the Hong Kong Stock Exchange [1] Company Overview - Hanx Biopharmaceuticals is an innovative biotech company specializing in structural biology, translational medicine, and clinical development, with a focus on building an innovative pipeline since 2016 [1] - The company has developed a core product and nine other pipeline candidates, including three clinical-stage candidates targeting oncology (HX009, HX301, HX044) and seven preclinical candidates, which include antibody-drug conjugates, bispecific antibodies, and monoclonal antibodies targeting autoimmune and oncology markets [1] Shareholder Information - A total of 15 shareholders will convert their shares, with the largest shareholding being 55,300,000 shares from Cai Zhang Biotechnology (Hangzhou) Co., Ltd. [2] - Other significant shareholders include Hanx Biopharmaceuticals (HK) Limited with 17,793,640 shares and Beijing Longpan Biopharmaceutical Venture Capital Center (Limited Partnership) with 12,860,470 shares [2] - The total number of shares being converted amounts to 117,897,830 shares [2]

Core Viewpoint - Hanse Aitai Biopharmaceutical Technology (Wuhan) Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, with ICBC International as the sole sponsor, despite being in a loss-making position for the fiscal years 2023 and 2024 [1][4]. Company Overview - Hanse Aitai is an innovative biotechnology company specializing in structural biology, translational medicine, and clinical development, with a pipeline that includes one core product and nine other candidate products [4][6]. - The core product, HX009, is a self-developed PD-1/SIRPα dual-function antibody fusion protein, which has completed Phase I clinical trials in Australia and China [4][5]. Product Pipeline - The company has three ongoing clinical projects for HX009 in China, targeting advanced melanoma, relapsed/refractory Epstein-Barr virus-positive non-Hodgkin lymphoma, and advanced biliary tract cancer [5]. - Two other major products, HX301 and HX044, are in clinical stages, focusing on cancer treatment. HX301 is a multi-target kinase inhibitor, while HX044 is a novel dual-function anti-CTLA-4 antibody SIRPα fusion protein [5][6]. Financial Performance - For the fiscal years 2023 and 2024, the company reported other income and revenue of approximately RMB 6.664 million and RMB 7.681 million, respectively, while incurring losses of about RMB 85.16 million and RMB 117 million [6][8]. - The company has a total of ten candidate drugs in its pipeline, with eight targeting oncology and two for autoimmune diseases [6].